IPR Tracker: Mylan and Genentech Settle Humanized Antibodies IPRs


We have been following the IPRs filed by Mylan against Genentech’s U.S. Patent No. 6,407,213, which relates to humanized antibody polypeptides and methods for their preparation and use.

On Tuesday, March 7th, the parties filed motions in IPR2016-0193 and IPR2016-01694 asking the Board to terminate the IPRs due to settlement.  No institution decision had as yet been made in either petition.

For more biosimilar news, stay tuned to Big Molecule Watch.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide